How much does a box of brigatinib/brigatinib cost?

Brigatinib/Brigatinib (Brigatinib) is an imported and original targeted therapy drug. It is mainly used to treat non-small cell lung cancer that has spread to other parts of the body (metastasis) after other treatment methods have failed. Its domestic pricing is relatively high, but since it has been included in the National Medical Insurance Category B Catalog, patients can enjoy a certain degree of reimbursement reductions and exemptions within the scope of medical insurance payment, thus reducing the actual burden. The common specifications of the original brigatinib drug currently on the market include: 30mg 14 tablets and 2 tablets, 90mg 7 tablets, 90mg 7 tablets and 4 tablets, and 180mg 7 tablets and 4 tablets, etc., making it easier for doctors to adjust dosage and formulate treatment plans based on individual patient conditions.

According to market price estimates from public channels, a box of brigatinib is usually priced between RMB 8,000 to 12,000 yuan. The specific price may vary according to region, pricing policy and medical insurance reimbursement ratio. For example, the regular package price of 180 mg 28 tablets is around RMB 10,000, and even with medical insurance, the out-of-pocket cost may reach several thousand yuan per box. The high cost of medication has become a real challenge in the long-term treatment of many ALK-positive lung cancer patients, so many people have begun to pay attention to the overseas generic drug market.

At present, pharmaceutical companies in countries such as Laos and Bangladesh have produced affordable generic versions of brigatinib. Common specifications such as90mg*30 tablets are priced at about 500 yuan, which is much lower than the price of the original drug. However, its ingredients are consistent with the original drug. Some patients obtain it through overseas channels as an economic alternative for long-term treatment.

Overall, the price difference of brigatinib reflects the imbalance in global drug accessibility, and further illustrates that accelerating the research and development of domestic generic drugs will become one of the important ways for patients to protect their rights to use drugs in the future.

Reference materials:https://www.alunbrig.com/